ITGA2 and nasopharyngeal carcinoma: If ITGA2 C807T polymorphism is verified as a valid prognostic marker for NPC patients, the possibility exists for customizing treatment modalities for individuals with ITGA2 C807 T/T genotype in an attempt to enhance survival.